Literature DB >> 30310232

Cancer stem cell pipeline flounders.

Ken Garber.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 30310232     DOI: 10.1038/nrd.2018.157

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

Review 1.  Cancer Stem Cells-Key Players in Tumor Relapse.

Authors:  Monica Marzagalli; Fabrizio Fontana; Michela Raimondi; Patrizia Limonta
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

2.  Gigantol Targets Cancer Stem Cells and Destabilizes Tumors via the Suppression of the PI3K/AKT and JAK/STAT Pathways in Ectopic Lung Cancer Xenografts.

Authors:  Nattanan Losuwannarak; Arnatchai Maiuthed; Nakarin Kitkumthorn; Asada Leelahavanichkul; Sittiruk Roytrakul; Pithi Chanvorachote
Journal:  Cancers (Basel)       Date:  2019-12-17       Impact factor: 6.639

3.  Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.

Authors:  Shuhei Suzuki; Masashi Okada; Tomomi Sanomachi; Keita Togashi; Shizuka Seino; Atsushi Sato; Masahiro Yamamoto; Chifumi Kitanaka
Journal:  J Biol Chem       Date:  2020-10-28       Impact factor: 5.157

4.  A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).

Authors:  Lori J Goldstein; Mauro Mansutti; Christelle Levy; Jenny C Chang; Stephanie Henry; Isaura Fernandez-Perez; Jana Prausovà; Elzbieta Staroslawska; Giuseppe Viale; Beth Butler; Susan McCanna; Pier Adelchi Ruffini; Max S Wicha; Anne F Schott
Journal:  Breast Cancer Res Treat       Date:  2021-09-03       Impact factor: 4.872

Review 5.  Breast Cancer Stem Cell Membrane Biomarkers: Therapy Targeting and Clinical Implications.

Authors:  Inês Conde; Ana Sofia Ribeiro; Joana Paredes
Journal:  Cells       Date:  2022-03-09       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.